GSK Reviews Options For European Business, Adopts New Manufacturing Processes
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline will implement a new £1.5 billion restructuring program to improve commercial efficiencies in Europe and adopt new manufacturing processes, following sales and profits shortfalls in 2012.